Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.91)
# 1,547
Out of 4,886 analysts
45
Total ratings
35.29%
Success rate
64.39%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCR NovoCure | Initiates: Buy | $30 | $17.31 | +73.31% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.06 | +1,975.47% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $10.51 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $6.79 | +253.46% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $19.30 | +547.83% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.17 | +731.41% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.59 | +633.59% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.97 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $5.85 | +10,156.41% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $203.72 | -61.14% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $53.11 | +191.85% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.04 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.95 | +405.05% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4,080 | $3.34 | +122,238.83% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $2.46 | +73,070.73% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $40.27 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.44 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.93 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $4.70 | +31,814.89% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.32 | +27,008.43% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.95 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $15.46 | +967.27% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $48.95 | +359.65% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.51 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.68 | - | 2 | Jan 4, 2017 |
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $17.31
Upside: +73.31%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.06
Upside: +1,975.47%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $10.51
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $6.79
Upside: +253.46%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $19.30
Upside: +547.83%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.17
Upside: +731.41%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.59
Upside: +633.59%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.97
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $5.85
Upside: +10,156.41%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $203.72
Upside: -61.14%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $53.11
Upside: +191.85%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $9.04
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $4.95
Upside: +405.05%
Apr 30, 2021
Initiates: Outperform
Price Target: $4,080
Current: $3.34
Upside: +122,238.83%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $2.46
Upside: +73,070.73%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $40.27
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.44
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $2.93
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $4.70
Upside: +31,814.89%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $3.32
Upside: +27,008.43%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.95
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $15.46
Upside: +967.27%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $48.95
Upside: +359.65%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $5.51
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.68
Upside: -